Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 15 03 2021
revised: 24 09 2021
accepted: 07 11 2021
pubmed: 15 11 2021
medline: 11 3 2022
entrez: 14 11 2021
Statut: ppublish

Résumé

The MUTYH gene encodes a DNA glycosylase that prevents G:C→T:A transversions. Patients with biallelic pathogenic germline MUTYH variants develop an adenomatous polyposis called MUTYH-associated polyposis (MAP). Endometrial cancers have been reported in patients with MAP, but the role of MUTYH loss of function in the oncogenesis remains unclear. We report for the first time a case of endometrial carcinoma with excess of G:C→T:A transversions in a 61-year-old patient with MAP. Single nucleotide variants of interest, Tumor Mutational Burden (TMB) and somatic mutation profile were obtained from Next-Generation Sequencing (NGS). The Tumor-Infiltrating Lymphocyte (TIL) level and immune infiltrate phenotype were assessed. The endometrial cancer had a high TMB (31.5 variants/Mb) with enrichment in G:C→T:A transversions and the presence of a driver pathogenic variant c.34G>T, p.(Gly12Cys) in KRAS, suggesting a role of MUTYH loss of function in oncogenesis. MUTYH loss of function could be involved in endometrial cancer in patients with MAP.

Identifiants

pubmed: 34775073
pii: S1769-7212(21)00251-2
doi: 10.1016/j.ejmg.2021.104385
pii:
doi:

Substances chimiques

DNA Glycosylases EC 3.2.2.-
mutY adenine glycosylase EC 3.2.2.-

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104385

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Marie-Charlotte Villy (MC)

Département de Génétique (Department of Genetics), Institut Curie, Paris, France.

Julien Masliah-Planchon (J)

Département de Génétique (Department of Genetics), Institut Curie, Paris, France; Paris Sciences & Lettres Research University, Paris, France.

Bruno Buecher (B)

Département de Génétique (Department of Genetics), Institut Curie, Paris, France; Paris Sciences & Lettres Research University, Paris, France; Réseau PRED-IdF, Institut Curie, Paris, France.

Clément Beaulaton (C)

Paris Sciences & Lettres Research University, Paris, France; Service de Pathologie (Department of Pathology), Institut Curie, Paris, France.

Anne Vincent-Salomon (A)

Paris Sciences & Lettres Research University, Paris, France; Service de Pathologie (Department of Pathology), Institut Curie, Paris, France.

Dominique Stoppa-Lyonnet (D)

Département de Génétique (Department of Genetics), Institut Curie, Paris, France; Université de Paris, Inserm U830, Paris, France.

Chrystelle Colas (C)

Département de Génétique (Department of Genetics), Institut Curie, Paris, France; Paris Sciences & Lettres Research University, Paris, France. Electronic address: chrystelle.colas@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH